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Abstract
Ischemia-reperfusion (I/R) injury is an important cause of liver damage occur-
ring during surgical procedures. In liver resection, I/R causes post-operative 
transaminasemia and liver function failure. In liver transplantation, I/R causes graft 
dysfunction, ranging from biochemical abnormalities to primary non-function of 
the transplanted organ. Ischemic preconditioning is a surgical strategy to reduce the 
severity of I/R and improve post-operative outcomes by prior exposure to a brief 
period of vascular occlusion directly to the target organ or remotely to a distant 
vascular bed. This chapter aims to discuss the different ischemic preconditioning 
strategies in both liver resection surgery and liver transplantation. In addition, we 
will describe the differences of such surgical strategies in both steatotic and non-
steatotic livers in both preclinical experiments and clinical practice. Such informa-
tion may be useful to guide the design of the effective ischemic preconditioning 
methods in the surgery of hepatic resections and liver transplantation.
Keywords: ischemia-reperfusion injury, liver resections, liver transplantation, 
ischemic preconditioning, remote ischemic preconditioning
1. Introduction
Ischemia-reperfusion (I/R) injury is a phenomenon in which cellular damage 
in a hypoxic organ is accentuated following the oxygen restoration [1–3], being a 
major pathophysiological event and cause of morbidity and mortality in liver resec-
tions and transplantation [4]. Despite the attempts to solve this problem, hepatic 
I/R is an unresolved problem. In addition, hepatic steatosis is a major risk factor for 
liver surgery, as it is associated with an increased complication index and postoper-
ative mortality after major liver resection and transplantation, since steatotic livers 
show impaired regenerative response and reduced tolerance to I/R injury compared 
with non-steatotic ones. Of note, the prevalence of steatosis ranges from 24 to 45% 
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of the population and consequently a further increase in the number of steatotic 
livers submitted to surgery is to be expected [5]. These observations highlight the 
need to develop protective strategies in liver surgical conditions.
The mechanisms involved in liver I/R injury are complicated, mainly including 
microcirculation failure and oxidative stress [4]. A wide range of strategies has 
been attempted in order to mitigate I/R injury, mainly pharmacological treatments 
focused on gene therapy, improvement of preservation solutions, among others. 
However, an effective treatment is still lacking [4] since is difficult to achieve by 
targeting individual mechanism. Surgical strategies such as the ischemic precondi-
tioning (IPC) technique noted for its effectiveness, as it activates several protective 
pathways against I/R injury in experimental models should be considered. IPC can 
be either applied directly to the target organ [6] or remotely (RIPC) to a distant 
vascular bed [7]. The benefits of the IPC and RIPC observed in experimental mod-
els of hepatic warm and cold ischemia [8, 9] prompted human trials of ischemic 
preconditioning. However, controversial results have been showed in the clinical 
practice. Therefore, the present chapter aims to describe the current knowledge of 
the IPC and RIPC in liver resections and liver transplantation of both steatotic and 
non-steatotic livers. In addition, the scientific controversies regarding the possible 
beneficial effects of these techniques, in experimental, translational and clinical 
studies in the setting of liver surgery will be discussed.
2. Ischemic preconditioning
Preconditioning the liver with ischemia involves a brief period of portal triad 
clamping usually between 5 and 15 min followed by a brief period of reperfusion 
(10–20 min) before a prolonged period of ischemia [10] (Figure 1). The exact mode 
of action of the IPC in the prevention of post-operative hepatic complication has 
not yet been fully comprehended. The molecular basis for IPC consists of a sequence 
of events in which in response to the triggers of IPC, a signal must be generated 
and transduced into an intracellular message leading to the effector mechanism 
Figure 1. 
Schematic illustration of ischemic preconditioning and remote ischemic preconditioning.
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of protection [11, 12]. As in the pathophysiology of hepatic I/R, in the modulation 
of hepatic injury induced by IPC, there is a complex interaction between different 
mechanisms and cell types [13].
2.1 IPC in experimental models
Over the years, studies with experimental animal models have reported numer-
ous positive effects of IPC on the alleviation of hepatic I/R injury and improve-
ments of post-operative liver functioning. Various combinations of ischemia and 
reperfusion periods have been tested showing similar beneficial effects: lower 
aminotransferase levels, reduced hepatocellular injury, and higher survival rates 
[14]. IPC protected against mitochondrial ROS and thus reduce the oxidative stress-
mediated damage in liver I/R injury [15–18]. However, Rüdiger et al. showed that 
IPC is beneficial in liver submitted to an ischemic period of up to 75 min, but not for 
more prolonged ischemia [19].
2.1.1 IPC in warm ischemia without liver resection
IPC modulates several molecular pathways involving in I/R. When long periods 
of liver ischemia occur in hepatectomy or transplantation, the lack of oxygenation 
induces the rapid ATP consume to generate energy for cellular metabolism, resulting 
in adenosine production. The accumulation of adenosine provokes its transforma-
tion to hypoxanthine and xanthine leading to ROS production. IPC (5 min of 
ischemia/10 min reperfusion) modulates oxidative stress since reduces the accumu-
lation of xanthine and the conversion of xanthine dehydrogenase (XDH) to xanthine 
oxidase (XO). IPC (5 min of ischemia/10 min reperfusion) inhibits this ROS generat-
ing system, xanthine/XOD [11–13]. The activation of adenosine receptor A2 induced 
by IPC stimulates the activity of various intracellular kinases, like protein kinase C 
(PKC)-specifically PKC-δ- and p38 mitogen-activated protein kinase (p38MAPK) 
[20]. The activation of p38 and c-Jun N-terminal kinase (JNK-1) induced by IPC 
(10 min of ischemia/10 min reperfusion) is associated with increased cyclin D1 
expression and entry into the cell cycle [21]. In addition to this, activation of p38 
by different pharmacological strategies mimicking IPC effects, including agonists 
of the adenosine A2 receptor, carbon monoxide (CO), NO, and atrial natriuretic 
peptide (ANP) has been considered to be a crucial mechanism of hepatoprotection 
in the setting of liver surgery [22]. Moreover, autophagic flux is enhanced by liver 
IPC (10 min of ischemia/10 min reperfusion), since endothelial nitric oxide synthase 
(eNOS)-derived NO activates autophagy via phosphorylation of p38 MAPK [23]. 
On the other hand, the mechanism involved in the benefits of IPC might be differ-
ent dependently of the type of the liver [1]. Indeed, in the presence of steatosis, IPC 
(5 min of ischemia/10 min reperfusion) reduces MAPK activation (JNK and p38), 
and this is associated with protection against hepatic I/R injury [24, 25]. The involve-
ment of sirtuin-1 (SIRT1) induction in the benefits of IPC (5 min of ischemia/10 min 
reperfusion) on normothermic hepatic conditions has been reported [26]. Thus, 
SIRT1 inhibition decreased the expression of extracellular signal-regulated protein 
kinases (ERK) and augmented p38 protein levels [26]. ERK activation during IPC 
(5 min of ischemia/10 min reperfusion) protects against I/R injury in steatotic livers, 
by inhibiting apoptosis [27], whereas treatment with a p38 activator abolished the 
benefits of IPC on hepatic damage [24]. In addition, inactivation of GSK-3β by 
IPC (10 min of ischemia/10–15 min reperfusion) induces β-catenin signaling and 
subsequently up-regulates anti-apoptotic factors, such as Bcl-2 and survivin, leading 
to a significant amelioration of liver I/R injury [28, 29]. Figure 2 shows some of the 
protective mechanisms of IPC in the hepatic I/R injury.
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2.1.2 IPC in liver resections under warm ischemia
The beneficial effects of IPC (10 min of ischemia/5 min reperfusion) in liver 
partial hepatectomy (PH) have been shown to be linked to better ATP recovery, 
NO production, antioxidant activities, and regulation of endoplasmic reticulum 
stress. All of this limited mitochondrial damage and apoptosis. In addition, the 
ERK1/2 and p38 MAPK activation induced by IPC in PH favors liver regeneration 
[30]. Furthermore, IPC (10 min of ischemia/10 min of reperfusion) can initiate 
hepatocyte proliferation action by a signaling mechanism involving TNF-α/IL-6 
signal pathway [31]. In contrast, Qian et al. found that IPC impaired residual liver 
regeneration after major PH without portal blood bypass in rats. In this case, IPC 
was of 5 min ischemia/10 min reperfusion [32]. Another study testing regenera-
tive capacity of the liver after IPC (10 min ischemia/10 min reperfusion) and PH 
showed that, despite IPC decreased hepatic injury, it did not influence the regenera-
tion up to 48 h [33].
2.1.3 IPC in reduced-size orthotopic liver transplantation
In a reduced-size orthotopic liver transplantation (ROLT) rat model, IPC 
(10 min ischemia/10 min reperfusion) has been suggested that potentiates hepa-
tocyte proliferation via TNF-α/IL-6-dependent pathway [34]. In addition, authors 
described that IPC inhibits IL-1 through NO, increases HGF, and reduces TGF-β to 
finally promote regeneration [34]. In addition, by another pathway independent 
Figure 2. 
Protective mechanisms propose of ischemic preconditioning and remote ischemic preconditioning in the 
hepatic ischemia-reperfusion injury. A2-R: adenosine 2 receptor; AMP: adenosine monophosphate; AMPK: 
AMP-activated protein kinase; ATF-2: activating transcription factor-2; ATP: adenosine triphosphate; 
cGMP: guanosine 3′,5′-cyclic monophosphate; eNOS: endothelial nitric oxide synthase; ER: endoplasmic 
reticulum; ET-1: endothelin-1; GSH: glutathione; HO-1: heme oxygenase-1; HSF-1: heat shock transcription 
factor-1; HSP72: heat-shock protein 72; IL: interleukin; iNOS: inducible nitric oxide synthase; JNK: jun 
N-terminal kinase; MAPK: mitogen-activated protein kinase; MEF2c: myocyte enhancer factor-2; MIF: 
macrophage migration inhibitory factor; NF-κB: factor nuclear factor-kappa B; NO: nitric oxide; PI3K: 
phosphatidylinositol 3-kinase; PKC: protein kinase C; PLC: phospholipase C; ROS: reactive oxygen species; 
STAT3: signal transducer and activator of transcription-3; TNF: tumor necrosis factor; X/XOD: xanthine/
xanthine oxidase.
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of NO, IPC induced over-expression of heat shock protein 70 (HSP70) and heme-
oxigenase-1 (HO-1) [35]. HO-1 protects against I/R injury, whereas the benefits 
resulting from HSP70 are mainly related to hepatocyte proliferation [35]. In addi-
tion, when steatotic grafts from living donors were transplanted applying IPC, 
the incidence of necrosis was reduced and the expression of both pro-autophagic 
beclin-1 and LC3 was increased [36]. On the other hand, in a rat model of ROLT 
with 70 or 90% hepatectomy, IPC (10 min ischemia/15 min reperfusion) impaired 
hepatic proliferative response by decreasing IL-6 and blunting cell cycle progression 
through a mechanism at least partially independent of STAT3 [37].
2.1.4 IPC in orthotopic liver transplantation
IPC (5 min ischemia/10 min reperfusion) has protected liver grafts in an experi-
mental model of orthotopic liver transplantation (OLT) by modulation of xanthine/
XOD system [38]. IPC reduced cAMP generation, thus ameliorating hepatic injury 
and survival of recipients with steatotic grafts [39]. In addition, AMPK activa-
tion by IPC (5 min ischemia/10 min reperfusion) increased the accumulation of 
adiponectin in steatotic liver grafts. This increased resistin and activated PI3K/Akt 
pathway, thus protecting steatotic livers against damage that follows transplantation 
[40]. However, it should be noted that in experimental liver transplantation from 
cadaveric donors, brain death abrogates the benefits of IPC (5 min ischemia/10 min 
reperfusion) in both steatotic and non-steatotic liver transplantation [41, 42]. 
Indeed, in the setting of liver transplantation, the inflammatory response induced 
by brain dead, present in the liver before the induction of IPC, would interact with 
various mechanistic aspects of IPC and block the eventual IPC response. Thus, 
Jimenez-Castro et al. have demonstrated that the treatment with acetylcholine pro-
tected liver grafts from the deleterious effects induced by brain death [41]. Under 
these conditions, the application of IPC was useful to improve the post-operative 
outcomes after transplantation.
In addition to the liver, the benefits of IPC in experimental models of warm 
ischemia and liver transplantation have been observed in extrahepatic organs. Thus, 
IPC protects against lung damage associated with liver transplantation. The applica-
tion of IPC in liver before I/R can prevent the release of both TNF and xanthine/
XOD from the liver to the circulation. This regulated the P-selectin up-regulation 
and the neutrophil accumulation in remote organs such as lung and splanchnic 
organs [43].
2.2 IPC in clinical trials
The benefits of IPC observed in experimental models of hepatic resections 
and liver transplantation [8, 9] prompted human trials of IPC. The benefits of 
this surgical strategy have been evidenced in patients submitted to liver resec-
tions, protecting both steatotic and non-steatotic livers [44]. However, different 
results have been reported on the effects of IPC in the clinical practice of liver 
transplantation [45, 46].
2.2.1 IPC in liver resections
The first clinical trial testing IPC in patients undergoing major PH was reported 
by Clavien et al. [47]. Authors conclude that IPC (10 min ischemia/10 min reper-
fusion) is a protective strategy against hepatic ischemia in humans, particularly 
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in young patients requiring a prolonged period of inflow occlusion and in the 
presence of steatosis [44, 47]. Other clinical trials also suggest that IPC (10 min 
ischemia/10 min reperfusion) provides both better intraoperative hemodynamic 
stability and anti-ischemic effects compared with intermittent clamping [48, 49]. 
Regarding the molecular basis of IPC (10 min ischemia/10 min reperfusion) in clini-
cal PH, its beneficial effects have been shown to be linked to the down-regulation 
of potentially cytotoxic functions of PMNLs elicited by the Pringle Maneuver [50]. 
In addition, IPC (10 min ischemia/15 min reperfusion) increased the generation 
of adenosine and attenuated the degradation of purines in patients undergoing 
PH. Moreover, IPC appeared to attenuate apoptotic response of the liver remnant 
after resection [51]. Other clinical trial revealed that IPC (10 min ischemia/10 min 
reperfusion) stimulated the expression of the IL-1-RA, inducible nitric oxide syn-
thase (iNOS), and Bcl-2 which decreased the inflammatory response and abrogated 
liver I/R injury [52]. Interestingly, since the ischemic period and pathophysiology 
are similar in partial hepatectomy and living donor liver transplantation, IPC could 
reduce damage and improve liver regeneration failure, a relevant risk factor in 
living donor liver transplantation [34]. Moreover, IPC could be implemented as an 
appropriate surgical strategy for the use of suboptimal livers, such as steatotic ones, 
in the clinical practice. Different results indicate that in patients with liver cirrhosis, 
IPC (5 min ischemia/5 min reperfusion) has been a suitable method to decrease liver 
I/R injury [53, 54]. Recently, the protective mechanism of IPC in patients with liver 
cirrhosis subjected to PH has been associated with changes in MAPK pathways [54]. 
In contrast, IPC applied for 15 min followed by 5 min reperfusion did not improve 
liver tolerance to I/R injury after PH in patients with liver cirrhosis [55]. In fact, 
RIPC did not induce changes in the postoperative levels of transaminases, bilirubin, 
and albumin nor reduced the morbidity and mortality rates and the duration of 
hospitalization [55].
2.2.2 IPC in orthotopic liver transplantation
Clinical trials in liver transplantation report different results on the effects of IPC 
against hepatic I/R injury. An IPC of 10 min ischemia/10 min reperfusion before 
liver transplantation reduced inflammatory response, improved ischemia tolerance, 
and decreased early graft function [56]. However, although the application of IPC 
(10 min ischemia/15 min reperfusion) reduced hepatocellular necrosis, it showed no 
clinical benefits [57]. In the largest prospective randomized trial of 10 min period 
IPC in liver transplantation from cadaveric donors, I/R injury was greater when IPC 
was applied [45], and it was called the “IPC paradox.” This was in accordance with 
the results obtained in experimental model of liver transplantation from cadaveric 
donors indicating that brain death abrogates the benefits of IP on post-operative 
outcomes [41, 42]. In fact, a microarray analysis in a randomized trial of 10 min IPC 
in deceased donor liver transplantation identified alteration of the expression of dif-
ferent antioxidant, immunological, lipid biosynthesis, cell development and growth 
transcripts, which are associated with hepatic damage [58].
3. Remote ischemic preconditioning
RIPC is a surgical technique by which preconditioning of one organ or vascular 
bed provides protection to distant organs or vascular beds during a sustained period 
of ischaemia (Figure 1). Few experimental and clinical studies, most of them from 
the last years, have addressed the effects of RIPC in livers submitted to I/R.
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3.1 RIPC in experimental models
3.1.1 RIPC in warm ischemia without liver resection
When RIPC is applied in the hind limb, it reduced hepatic warm I/R injury of 
mice, rats, and rabbits. RIPC (5–10 min ischemia/5–10 min reperfusion) has been 
shown to improve hepatic oxygenation and microcirculation and to reduce hepatic 
acidosis and damage [59, 60]. RIPC (4 min ischemia/4 min reperfusion) induced 
eNOS activation, leading to NO production to preserve sinusoidal structure and 
blood flow [61]. In addition, RIPC (5 min ischemia/5 min reperfusion) regulated 
the expressions of iNOS and eNOS and the expressions of miR-34a, miR-122, and 
miR-27b injury related miRs in fatty livers, thus attenuating I/R injury [62, 63]. 
RIPC (10 min ischemia/10 min reperfusion) also induced the up-regulation of 
HO-1, induced autophagy, and then reduced the damaged mitochondria to inhibit 
apoptosis and eventually protect hepatic cells from I/R injury [64, 65]. Moreover, 
RIPC (5 min ischemia/5 min reperfusion) reduced neutrophil activation and 
adhesion and TNF-α [66]. Controversial results have been described in a rat model 
in which RIPC protocol included 3 cycles of 10 min ischemia interspersed with 
10 min of reperfusion periods [67]. Regarding the hemodynamic and microcircu-
latory alterations, RIPC protocol had beneficial effect; however, the histopatho-
logical findings were paradox [67, 68]. In addition to RIPC in the hind limb, when 
RIPC (5 min ischemia/5 min reperfusion) is applied in kidney, it has also been 
shown to protect liver against I/R injury, improving blood flow, histology, and 
redox-state [69]. Figure 2 shows some of the protective mechanisms of RIPC in the 
hepatic I/R injury.
3.1.2 RIPC in liver resections
A recent study in mice showed that RIPC (3 cycles of 5 min of ischemia each 
followed by 5 min of reperfusion) applied in the right femoral vascular bundle did not 
affect regeneration after 70%-PH [70]. However, of clinical interest, the same proto-
col of RIPC improved liver weight gain and hepatocyte mitoses after 90%-PH [70].
3.1.3 RIPC in orthotopic liver transplantation
In an experimental model of OLT, RIPC based on 4 cycles of 5 min of ischemia 
and 5 min of reperfusion was applied on the infrarenal aorta. The results sug-
gested that RIPC might confer potent protection against the detrimental effects 
of I/R injury including apoptosis and inflammation [71]. In addition, authors 
suggest that HO-1 overexpression could play an orchestrating role in RIPC (5 min 
ischemia/5 min reperfusion)-mediated organ protection [71]. In addition, a recent 
study showed that the same protocol of RIPC also exhibits protective effects, 
as indicated by increased portal venous flow and microcirculation, as well as 
decreased AST and ALT levels and a reduced Suzuki score in a model of OLT [72]. 
Authors suggest that the RIPC inhibited the macrophage migration inhibitory 
factor (MIF), which resulted in the modulation of further downstream pro-survival 
mechanisms (iNOS, RISK-, SAFE-pathways), protecting graft injury [72].
3.2 RIPC in clinical trials
Only three studies dated in 2017 and 2018 have addressed the effects of RIPC in 
the clinical liver surgery.
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3.2.1 RIPC in liver resections
In major HP, RIPC was shown to reduce liver I/R injury as indicated by a reduc-
tion in post-operative transaminases and increased ICG clearance [73]. To induce 
RIPC, a tourniquet was inflated to induce 10 min of ischemia and then deflated 
for 10 min to reperfuse the leg. This was repeated twice prior to commencing the 
operation. RIPC has potential to reduce liver injury following PH [73]. In addition, 
other clinical trial where RIPC was induced by three cycles of 5 min of ischemia of 
right upper limb followed by 5 min of reperfusion showed hepatic cytoprotective 
effects assessed by cholinesterase and bilirubin levels during liver resection [74]. 
Authors suggest that a shorter protocol of RIPC is safe and of equal effect, although 
the mechanisms of this effect must be investigated in future studies [74].
3.2.2 RIPC in orthotopic liver transplantation
The first trial to investigate the feasibility of RIPC in liver transplant recipients 
was addressing by Robertson et al. [75]. The trial involved randomization of adult 
recipients undergoing deceased donor liver transplantation. To induce RIPC, a 
tourniquet was inflated for 5 min and then deflated for 5 min to reperfuse the leg. 
This was repeated twice and completed prior to the transplant procedure. Authors 
demonstrated that RIPC is feasible, acceptable to patients and safe in this group of 
patients but clinical benefits within the first 3 months post transplantation were not 
detected [75]. Authors suggest that 5 min cycles are insufficient to create localized 
ischemia in the limb [75].
4. Conclusion
Surgical strategies such as the induction of IPC or RIPC could be of clinical 
interest in human liver resections and liver transplantation in both steatotic and 
non-steatotic livers. Both IPC and RIPC are easy to apply, inexpensive and does 
not require the use of drugs with potential side effects, but it requires a period 
of pre-ischemic manipulation for organ protection. These preconditioning tech-
niques have been demonstrated to be promising tools for the reduction of hepatic 
I/R injury in different warm and cold ischemia models. Therefore, the potential 
applications of IPC and RIPC in human liver surgery are numerous. The benefits of 
IPC and RIPC have been evidenced in patients submitted to partial hepatectomy in 
both steatotic and non-steatotic livers. In our view, IPC and RIPC could resolve, at 
least partially, the lack of liver grafts available for transplant, since it can improve 
the post-operative outcome of liver grafts from extended criteria donors. However, 
controversial results on the effects of IPC and RIPC have been reported in the 
clinical practice of liver transplantation. It should be considered that the underly-
ing mechanisms of both IPC and RIPC and their relevance in liver surgery remain 
poorly understood. Indeed, as stated along this chapter, most of the experimental 
studies have been focused on the molecular changes occurring during IPC and RIPC 
in non-brain-dead donors. Moreover, most of the experimental studies of IPC and 
RIPC have been performed only in I/R injury models, without hepatic resections or 
liver transplantation. The tolerance to I/R injury induced by either IPC or RIPC is 
dependently of the number of cycles of I/R and their duration as well as the surgi-
cal procedures. The clinical application of strategies designed at benchside will 
depend on the use of experimental models of IPC and RIPC that resemble as much 
as possible the clinical conditions. Multidisciplinary research groups should devote 
additional efforts to better understand the molecular mechanisms of IPC and RIPC 
9© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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during the different clinical liver surgery setting to ultimately develop useful surgi-
cal strategies aimed at reducing I/R damage.
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